Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

ClinicalTrials.gov ID: NCT02153645

Public ClinicalTrials.gov record NCT02153645. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was terminated early due to slow enrollment with 87 of 162 planned subjects enrolled. The purpose of this multi-center, randomized, double-blind, parallel-group, 16 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.

Study identification

NCT ID: NCT02153645
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Enrollment: 87 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 30 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 17, 2014
Primary completion: May 19, 2016
Completion: May 19, 2016
Last update posted: Feb 15, 2022

2014 – 2016

United States locations

U.S. sites: 26
U.S. states: 15
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85724	—
Not listed	Fountain Valley	California	92708	—
Not listed	Irvine	California	92697	—
Not listed	Pasadena	California	91105	—
Not listed	Reseda	California	91335	—
Not listed	Ventura	California	93001	—
Not listed	Ventura	California	93003	—
Not listed	Boulder	Colorado	80304	—
Not listed	Hollywood	Florida	33021	—
Not listed	Miami	Florida	33101	—
Not listed	North Palm Beach	Florida	33403	—
Not listed	Tampa	Florida	33612	—
Not listed	Chicago	Illinois	60612	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Baton Rouge	Louisiana	70810	—
Not listed	Ann Arbor	Michigan	48103	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Summit	New Jersey	07901	—
Not listed	Brooklyn	New York	11203	—
Not listed	Manhasset	New York	11020	—
Not listed	Patchogue	New York	11772	—
Not listed	Raleigh	North Carolina	27612	—
Not listed	Columbus	Ohio	43221	—
Not listed	Round Rock	Texas	78681	—
Not listed	Orem	Utah	84058	—
Not listed	Kirkland	Washington	98034	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02153645, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 15, 2022 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02153645 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →